Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial

Bram Rochwerg, Tina Millen, Peggy Austin, Michelle Zeller, Frédérick D'Aragon, Roman Jaeschke, Marie-Hélène Masse, Sangeeta Mehta, Francois Lamontagne, Maureen Meade, Gordon Guyatt, Deborah J Cook, Canadian Critical Care Trials Group, Bram Rochwerg, Tina Millen, Peggy Austin, Michelle Zeller, Frédérick D'Aragon, Roman Jaeschke, Marie-Hélène Masse, Sangeeta Mehta, Francois Lamontagne, Maureen Meade, Gordon Guyatt, Deborah J Cook, Canadian Critical Care Trials Group

Abstract

Introduction: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will change without direct randomised clinical trial (RCT) evidence. This pilot RCT will investigate the feasibility of a large-scale trial directly comparing low chloride with high chloride fluids in patients with septic shock.

Methods and analysis: This is a randomised, concealed, blinded parallel-group multicentre pilot trial. We will include adult critically ill patients with septic shock, defined as ongoing hypotension despite 1 L of fluid, or a serum lactate >4 mmol/L, who are within 6 hours of hospital presentation or rapid response team activation. We will exclude patients if they have an aetiology of shock other than sepsis, if they have acute burn injury, elevated intracranial pressure, intent to withdraw life support or previous enrolment in this or a competing trial. Following informed consent, patients will be randomised to a low chloride fluid strategy or a high chloride fluid strategy for the duration of their ICU stay or until 30 days postrandomisation. Clinicians, patients, families and research staff will be blinded. The primary outcome for this trial will be feasibility, assessed by consent rate, recruitment success and protocol adherence. Patient-important clinical outcomes include mortality, receipt of renal replacement therapy, intensive care unit and hospital lengths of stay and surrogate outcomes of incidence of acidosis, hyperkalaemia and acute kidney injury.

Ethics and dissemination: This pilot trial will test the feasibility of conducting the main trial, which will examine the effect of high versus low chloride fluids in patients with septic shock on patient-important outcomes.

Trial registration number: NCT02748382, registered 8 April 2016.

Protocol date: 1 July 2016.

Keywords: RCT; chloride; intravenous fluids; resuscitation; sepsis.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Rhodes A, Evans LE, Alhazzani W, et al. . Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017;43:304–77. 10.1007/s00134-017-4683-6
    1. Rochwerg B, Włudarczyk A, Szczeklik W, et al. . Fluid resuscitation in severe sepsis and septic shock: systematic description of fluids used in randomized trials. Pol Arch Med Wewn 2013;123:603–8. 10.20452/pamw.1972
    1. Rochwerg BZM, Millen T, Kavsak P, et al. . Chloride concentration of IV albumin solutions available at Canadianhospitals. Canadian Critical Care Forum Abstract, 2015.
    1. Yunos NM, Bellomo R, Hegarty C, et al. . Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012;308:1566–72. 10.1001/jama.2012.13356
    1. Rochwerg B, Alhazzani W, Sindi A, et al. . Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med 2014;161:347–55. 10.7326/M14-0178
    1. Young P, Bailey M, Beasley R, et al. . Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA 2015;314:1701–10. 10.1001/jama.2015.12334
    1. McIntyre LA, Fergusson DA, Cook DJ, et al. . Fluid resuscitation with 5% albumin versus normal saline in early septic shock: a pilot randomized, controlled trial. J Crit Care 2012;27:e311–6. 317 10.1016/j.jcrc.2011.10.007
    1. Smith OM, McDonald E, Zytaruk N, et al. . Enhancing the informed consent process for critical care research: strategies from a thromboprophylaxis trial. Intensive Crit Care Nurs 2013;29:300–9. 10.1016/j.iccn.2013.04.006
    1. Kho ME, Molloy AJ, Clarke F, et al. . CYCLE pilot: a protocol for a pilot randomised study of early cycle ergometry versus routine physiotherapy in mechanically ventilated patients. BMJ Open 2016;6:e011659 10.1136/bmjopen-2016-011659
    1. Lamontagne F, Meade MO, Hébert PC, et al. . Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 2016;42:542–50. 10.1007/s00134-016-4237-3
    1. Lin CY, Chen YC. Acute kidney injury classification: AKIN and RIFLE criteria in critical patients. World J Crit Care Med 2012;1:40–5. 10.5492/wjccm.v1.i2.40
    1. Finfer S. Reappraising the role of albumin for resuscitation. Curr Opin Crit Care 2013;19:315–20. 10.1097/MCC.0b013e3283632e42
    1. Morgan TJ. The ideal crystalloid - what is 'balanced'? Curr Opin Crit Care 2013;19:299–307. 10.1097/MCC.0b013e3283632d46
    1. Myburgh J. Advances in fluid resuscitation in critically ill patients: implications for clinical practice. Curr Opin Crit Care 2013;19:279–81. 10.1097/MCC.0b013e328363091e
    1. Raghunathan K, Shaw AD, Bagshaw SM. Fluids are drugs: type, dose and toxicity. Curr Opin Crit Care 2013;19:290–8. 10.1097/MCC.0b013e3283632d77
    1. Seymour CW, Angus DC. Making a pragmatic choice for fluid resuscitation in critically ill patients. JAMA 2013;310:1803 10.1001/jama.2013.280503

Source: PubMed

3
Předplatit